News
TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO
2017/6/5 TaiRx, Inc. (6580) [...]
TaiRx’s oral cancer drug with a promising forecast.
2016/3/28 […]
2017/6/15 TaiRx shows its [...]
2017/6/5 TaiRx, Inc. (6580) [...]
2016/06/17 This issue of [...]
2016/3/28 […]
2016/3/18 […]